UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___ to ___
Commission file number:
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
(Address of principal executive offices) |
(Zip code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐
|
Accelerated filer ☐ Smaller reporting company Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).
The number of shares outstanding of the registrant’s common stock as of August 12, 2022 was .
TABLE OF CONTENTS
| PART I – FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements (Unaudited) | 3 |
| Condensed Balance Sheets (Unaudited) | 4 | |
| Condensed Statements of Operations (Unaudited) | 5 | |
| Condensed Statements of Stockholders’ Deficit (Unaudited) | 6 | |
| Condensed Statements of Cash Flows (Unaudited) | 7 | |
| Condensed Notes to the Unaudited Financial Statements | 8 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 9 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 11 |
| Item 4. | Controls and Procedures | 11 |
| PART II – OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 12 |
| Item 1a. | Risk Factors Information | 12 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 12 |
| Item 3. | Defaults Upon Senior Securities | 12 |
| Item 4. | Mine Safety Disclosures | 12 |
| Item 5. | Other Information | 12 |
| Item 6. | Exhibits | 12 |
| Signatures | 13 | |
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CANCER CAPITAL CORP.
Condensed Financial Statements
June 30, 2022
(Unaudited)
| 3 |
Cancer Capital Corp.
Condensed Balance Sheets
(Unaudited)
| JUNE 30, 2022 | DEC 31, 2021 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | $ | ||||||
| Total current assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable – related party | $ | $ | ||||||
| Accounts payable | ||||||||
| Notes payable – related party | ||||||||
| Notes payable | ||||||||
| Accrued interest – related party | ||||||||
| Accrued interest | ||||||||
| Total current liabilities | ||||||||
| Total liabilities | ||||||||
| STOCKHOLDERS' DEFICIT | ||||||||
| Common stock, $ par value; shares authorized; shares issued and outstanding | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders' deficit | ( | ) | ( | ) | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 4 |
Cancer Capital Corp.
Condensed Statements of Operations
(Unaudited)
| FOR
THE THREE MONTHS ENDED JUNE 30, 2022 | FOR
THE THREE MONTHS ENDED JUNE 30, 2021 | FOR
THE SIX MONTHS ENDED JUNE 30, 2022 | FOR
THE SIX MONTHS ENDED JUNE 30, 2021 | |||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other expense | ||||||||||||||||
| Interest expense – related party | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax expense | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share – Basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average shares outstanding – Basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 5 |
Cancer Capital Corp.
Condensed Statements of Stockholders’ Deficit
For the three and six months ended June 30, 2022 and 2021
(Unaudited)
| Additional | Total | |||||||||||||||||||
| Common Stock | Paid-in | Accumulated | Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||
| Balance – December 31, 2020 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
| Net loss for the three months ended March, 2021 | — | ( | ) | ( | ) | |||||||||||||||
| Balance – March 31, 2021 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
| Net loss for the three months ended June 30, 2021 | — | ( | ) | ( | ) | |||||||||||||||
| Balance -- June 30, 2021 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
| Balance – December 31, 2021 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
| Net loss for the three months ended March 31, 2022 | — | ( | ) | ( | ) | |||||||||||||||
| Balance – March 31, 2022 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
| Net loss for the three months ended June 30, 2022 | — | ( | ) | ( | ) | |||||||||||||||
| Balance – June 30, 2022 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 6 |
Cancer Capital Corp.
Condensed Statements of Cash Flows
(Unaudited)
| FOR
THE SIX MONTHS ENDED JUNE 30, 2022 | FOR
THE SIX MONTHS ENDED JUNE 30, 2021 | |||||||
| Cash Flows from Operating Activities | ||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Adjustment to reconcile net loss to cash used by operating activities: | ||||||||
| Expenses paid by related party | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Increase in accounts payable | ||||||||
| Increase in accrued interest – related party | ||||||||
| Increase in accrued interest | ||||||||
| Net cash used by operating activities | ( | ) | ( | ) | ||||
| Cash Flows from Investing Activities | ||||||||
| Net cash provided by investing activities | ||||||||
| Cash Flows from Financing Activities | ||||||||
| Proceeds from notes payable | ||||||||
| Net cash provided by financing activities | ||||||||
| Increase in cash | ||||||||
| Cash at beginning of period | ||||||||
| Cash at end of period | $ | $ | ||||||
| Supplemental Cash Flow Information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for income taxes | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 7 |
Cancer Capital Corp.
Notes to the Condensed Financial Statements
(Unaudited)
June 30, 2022
NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION
The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2021 Annual Report on Form 10-K. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for year ending December 31, 2022.
NOTE 2 – GOING CONCERN
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.
The COVID-19 pandemic could have an impact on our ability to obtain financing to fund our operations. The Company is unable to predict the ultimate impact at this time.
NOTE 3 – RELATED PARTY TRANSACTIONS
During the six months ended June 30, 2022 and 2021, a shareholder invoiced
the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company
totaling $
A shareholder has loaned the Company funds in prior years. The notes bear
interest at
NOTE 4 – NOTES PAYABLE
During the six months ended June 30, 2022 and 2021, the Company was loaned
$
NOTE 5 – SUBSEQUENT EVENTS
The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.
| 8 |
FORWARD LOOKING STATEMENTS
The Securities and Exchange Commission (“SEC”) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “intend,” “expect,” “believe,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
In this report references to “Cancer Capital,” “the Company,” “we,” “us,” and “our” refer to Cancer Capital Corp.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Executive Overview
We have not recorded revenues since inception and we are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue. At this time management is unsure what effect the COVID-19 pandemic will have on our search for companies to combine with.
As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may complete a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.
We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.
If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.
| 9 |
Liquidity and Capital Resources
We have not recorded revenues from operations since inception and we have not established an ongoing source of revenue sufficient to cover our operating costs. We have relied primarily upon related parties and third parties to provide and pay for professional and operational expenses. At June 30, 2022, we had $20,453 cash and at December 31, 2021, we had $62. This increase in cash is due to a third-party loan. At June 30, 2022, total liabilities increased to $412,041 compared to $369,194 at December 31, 2021. Total liabilities primarily represent an increase in accounts payable and accrued interest for all notes payable and notes payable-related party for cash advances, consulting services and professional services provided by or paid for by a stockholder (See “Commitments and Obligations,” below).
We intend to obtain capital from management, significant stockholders and/or third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.
During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through funds provided by management, significant stockholders and/or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.
Results of Operations
We did not record revenues in either 2022 or 2021. General and administrative expense for the six months ended June 30, 2022 (“2022 six-month period”) was $11,960 compared to $9,200 the six months ended June 30, 2021 (“2021 six-month period”). General and administrative expense for the three months ended June 30, 2022 (“2022 second quarter”) was $2,850 compared to $3,800 for the three months ended June 30, 2021 (“2021 second quarter”)
Total other expense increased to $10,496 for the 2022 six-month period compared to $9,066 for the 2021 six-month period. Total other expense increased to $5,408 for the 2022 second quarter compared to $4,572 for the 2021 second quarter. Total other expense represents interest expense related to notes payable and notes payable - related party.
Our net loss increased to $22,456 for the 2022 six-month period compared to $18,266 for the 2021 six-month period. Our net loss increased $8,258 for the 2022 second quarter compared to $8,372 for the 2021 second quarter. Management expects net losses to continue until we acquire or merge with a business opportunity.
Commitments and Obligations
At June 30, 2022, we reported notes payable totaling $125,275 with accrued interest of $59,535. The increase was due to receipt of a $28,000 loan from a third party during the 2022 first quarter. We recorded notes payable-related party totaling $145,125 with accrued interest of $71,756. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand.
During the three months ended June 30, 2022, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $3,000 resulting in the Company owing the shareholder $9,000 at June 30, 2022.
At June 30, 2022 we owe vendors $1,350.
As of June 30, 2022 two lenders represent in excess of 95% of our accounts and notes payable.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.
Emerging Growth Company
We qualify as an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). A company qualifies as an emerging growth company if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December 8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend to, rely on exemptions from certain disclosure requirements
In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.
| 10 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable to smaller reporting companies.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were not effective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.
Changes to Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended June 30, 2022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
| 11 |
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.
ITEM 1A. RISK FACTORS
As a smaller reporting company, we are not required to provide the information required by this Item.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS
Part I Exhibits
| No. | Description |
| 31.1 | Principal Executive Officer Certification |
| 31.2 | Principal Financial Officer Certification |
| 32.1 | Section 1350 Certification |
Part II Exhibits
| No. | Description |
| 3(i).1 | Articles of Incorporation, dated April 11, 1997 (Incorporated by reference to exhibit 3.1 of the Form 10-SB, File No. 000-32363, filed February 20, 2001) |
| 3(i).2 | Wyoming Articles of Domestication for Cancer Capital, dated April 28, 2016 (Incorporated by reference to exhibit 3(i) to Form 10-Q, filed May 13, 2016) |
| 3(ii) | Bylaws of Cancer Capital, dated May 2, 2016 (Incorporated by reference to exhibit 3(ii) to Form 10-Q, filed May 13, 2016) |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Calculation Linkbase Document |
| 101.CAL | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Presentation Linkbase Document |
| 12 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Date: August 12, 2022 |
CANCER CAPITAL CORP.
By: /s/ John W. Peters John W. Peters President and Director Principal Financial Officer |
13
Exhibit 31.1
PRINCIPAL EXECUTIVE OFFICER CERTIFICATION
I, John W. Peters, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report. |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): |
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: August 12, 2022 |
/s/ John W. Peters John W. Peters Principal Executive Officer |
Exhibit 31.2
PRINCIPAL FINANCIAL OFFICER CERTIFICATION
I, John W. Peters, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report. |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): |
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: August 12, 2022 |
/s/ John W. Peters John W. Peters Principal Financial Officer |
Exhibit 32.1
CANCER CAPITAL CORP.
CERTIFICATION OF PERIODIC REPORT
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
18 U.S.C. Section 1350
The undersigned executive officer of Cancer Capital Corp. certifies pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:
| a. | the quarterly report on Form 10-Q of Cancer Capital Corp. for the quarter ended June 30, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| b. | the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cancer Capital Corp. |
|
Date: August 12, 2022 |
/s/ John W. Peters John W. Peters Principal Executive Officer Principal Financial Officer |
Condensed Balance Sheets (Unaudited) - USD ($) |
Jun. 30, 2022 |
Dec. 31, 2021 |
|---|---|---|
| CURRENT ASSETS | ||
| Cash | $ 20,453 | $ 62 |
| Total current assets | 20,453 | 62 |
| TOTAL ASSETS | 20,453 | 62 |
| CURRENT LIABILITIES | ||
| Accounts payable – related party | 9,000 | 6,000 |
| Accounts payable | 1,350 | |
| Notes payable – related party | 145,125 | 145,125 |
| Notes payable | 125,275 | 97,275 |
| Accrued interest – related party | 71,756 | 65,950 |
| Accrued interest | 59,535 | 54,844 |
| Total current liabilities | 412,041 | 369,194 |
| Total liabilities | 412,041 | 369,194 |
| STOCKHOLDERS' DEFICIT | ||
| Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding | 6,150 | 6,150 |
| Additional paid-in capital | 47,050 | 47,050 |
| Accumulated deficit | (444,788) | (422,332) |
| Total stockholders' deficit | (391,588) | (369,132) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 20,453 | $ 62 |
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares |
Jun. 30, 2022 |
Dec. 31, 2021 |
|---|---|---|
| Statement of Financial Position [Abstract] | ||
| Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
| Common Stock, Shares Authorized | 20,000,000 | 20,000,000 |
| Common Stock, Shares, Issued | 6,150,000 | 6,150,000 |
| Common Stock, Shares, Outstanding | 6,150,000 | 6,150,000 |
Condensed Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Income Statement [Abstract] | ||||
| Revenues | ||||
| Operating expenses | ||||
| General and administrative | 2,850 | 3,800 | 11,960 | 9,200 |
| Total operating expenses | 2,850 | 3,800 | 11,960 | 9,200 |
| Loss from operations | (2,850) | (3,800) | (11,960) | (9,200) |
| Other expense | ||||
| Interest expense – related party | (2,903) | (2,783) | (5,805) | (5,566) |
| Interest expense | (2,505) | (1,789) | (4,691) | (3,500) |
| Total other expense | (5,408) | (4,572) | (10,496) | (9,066) |
| Loss before income taxes | (8,258) | (8,372) | (22,456) | (18,266) |
| Income tax expense | ||||
| Net loss | $ (8,258) | $ (8,372) | $ (22,456) | $ (18,266) |
| Net loss per share – Basic and diluted | $ (0.00) | $ (0.00) | $ (0.00) | $ (0.00) |
| Weighted average shares outstanding – Basic and diluted | 6,150,000 | 6,150,000 | 6,150,000 | 6,150,000 |
Condensed Statements of Cash Flows (Unaudited) - USD ($) |
6 Months Ended | |
|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Cash Flows from Operating Activities | ||
| Net Loss | $ (22,456) | $ (18,266) |
| Adjustment to reconcile net loss to cash used by operating activities: | ||
| Expenses paid by related party | 3,000 | 3,000 |
| Changes in operating assets and liabilities: | ||
| Increase in accounts payable | 1,350 | 3,000 |
| Increase in accrued interest – related party | 5,806 | 5,566 |
| Increase in accrued interest | 4,691 | 3,500 |
| Net cash used by operating activities | (7,609) | (3,200) |
| Cash Flows from Investing Activities | ||
| Net cash provided by investing activities | ||
| Cash Flows from Financing Activities | ||
| Proceeds from notes payable | 28,000 | 3,700 |
| Net cash provided by financing activities | 28,000 | 3,700 |
| Increase in cash | 20,391 | 500 |
| Cash at beginning of period | 62 | 698 |
| Cash at end of period | 20,453 | 1,198 |
| Supplemental Cash Flow Information: | ||
| Cash paid for interest | ||
| Cash paid for income taxes | ||
NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| Accounting Policies [Abstract] | |
| NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION | NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION
The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2021 Annual Report on Form 10-K. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results to be expected for year ending December 31, 2022. |
NOTE 2 – GOING CONCERN |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| NOTE 2 – GOING CONCERN | NOTE 2 – GOING CONCERN
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.
The COVID-19 pandemic could have an impact on our ability to obtain financing to fund our operations. The Company is unable to predict the ultimate impact at this time. |
NOTE 3 – RELATED PARTY TRANSACTIONS |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| Related Party Transactions [Abstract] | |
| NOTE 3 – RELATED PARTY TRANSACTIONS | NOTE 3 – RELATED PARTY TRANSACTIONS
During the six months ended June 30, 2022 and 2021, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $3,000 and $3,000, respectively, resulting in the Company owing the shareholder $9,000 and $6,000 at June 30, 2022 and December 31, 2021, respectively.
A shareholder has loaned the Company funds in prior years. The notes bear interest at 8% and are due on demand. Notes payable – related party at June 30, 2022 and December 31, 2021 were $145,125 and $145,125, respectively. Accrued interest at June 30, 2022 and December 31, 2021 was $71,756 and $65,950, respectively. |
NOTE 4 – NOTES PAYABLE |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| Debt Disclosure [Abstract] | |
| NOTE 4 – NOTES PAYABLE | NOTE 4 – NOTES PAYABLE
During the six months ended June 30, 2022 and 2021, the Company was loaned $28,000 and $3,700, respectively. The notes bear interest at 8% and are due on demand. Notes payable at June 30, 2022 and December 31, 2021 were $125,275 and $97,275, respectively. Accrued interest at June 30, 2022 and December 31, 2021 was $59,535 and $54,844, respectively. |
NOTE 5 – SUBSEQUENT EVENTS |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| Subsequent Events [Abstract] | |
| NOTE 5 – SUBSEQUENT EVENTS | NOTE 5 – SUBSEQUENT EVENTS
The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements. |
NOTE 3 – RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) |
6 Months Ended | ||
|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
|
| Related Party Transactions [Abstract] | |||
| Costs and Expenses, Related Party | $ 3,000 | $ 3,000 | |
| Accounts Payable, Related Parties, Current | $ 9,000 | $ 6,000 | |
| Debt Instrument, Interest Rate During Period | 8.00% | 8.00% | |
| Notes Payable, Related Parties, Current | $ 145,125 | 145,125 | |
| Accrued Liabilities and Other Liabilities | $ 71,756 | $ 65,950 | |
NOTE 4 – NOTES PAYABLE (Details Narrative) - USD ($) |
6 Months Ended | ||
|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
|
| Debt Disclosure [Abstract] | |||
| Proceeds from Notes Payable | $ 28,000 | $ 3,700 | |
| Debt Instrument, Interest Rate During Period | 8.00% | 8.00% | |
| Notes Payable, Current | $ 125,275 | $ 97,275 | |
| Interest Payable, Current | $ 59,535 | $ 54,844 | |
5X,+H$
MO?&HUY_4A++XX#6!^"05<2M&/.D/98;/P94UF?X TXDULJV>RK%=#_ST,]I-
MR&8C%?)Q#%G=VA+P#^MLV*\'9?;I;0*IF8JT'2.UK\_L_C_7JGS[-_):4TZK
MG^$FHFB^ND3 I] #B%W4-.V4._)-A-6J4D;9D83O!'51_PDFG_P'4$L#!!0
M ( /MT#%4*QC/9T1H )1R 0 5 8VYC;"TR,#(R,#8S,%]L86(N>&UL
MW9U[<^.V>L;_[TR_ ^K3:9(9>WU+,MU-